Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 54, Issue 2, pp 261–268 | Cite as

Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing

  • Rohan AmeratungaEmail author
  • Klaus Lehnert
  • See-Tarn Woon
  • David Gillis
  • Vanessa L. Bryant
  • Charlotte A. Slade
  • Richard Steele
Article

Abstract

Common variable immunodeficiency disorders (CVID) are an enigmatic group of often heritable conditions, which may manifest for the first time in early childhood or as late as the eighth decade of life. In the last 5 years, next generation sequencing (NGS) has revolutionised identification of genetic disorders. However, despite the best efforts of researchers around the globe, CVID conditions have been slow to yield their molecular secrets. We have previously described the many clinical advantages of identifying the genetic basis of primary immunodeficiency disorders (PIDs). In a minority of CVID patients, monogenic defects have now been identified. If a causative mutation is identified, these conditions are reclassified as CVID-like disorders. Here we discuss recent advances in the genetics of CVID and discuss how NGS can be optimally deployed to identify the causal mutations responsible for the protean clinical manifestations of these conditions. Diagnostic criteria such as the Ameratunga et al. criteria will continue to play an important role in patient management as well as case selection and sequencing strategy design until the genetic conundrum of CVID is solved.

Keywords

CVID NGS IVIG CVID-like disorders 

Notes

Acknowledgements

We are extremely grateful to our patients for allowing us to undertake these studies for the benefit of others. We hope this discovery will benefit them and any future families with these disorders. We thank AMRF, A+ Trust, IDFNZ, ASCIA, and the Australian National Health and Medical Research Council (NHMRC, Program Grant 1054925) and Project 1127198 for grant support. We also receive support from Bloody Long Way (BLW). C.S. is supported by NHMRC postgraduate scholarship 1075666. We thank Dr. Kitty Croxson, ADHB, and LabPlus management for ongoing support. Bioinformatic analysis was supported by the New Zealand eScience Infrastructure. All studies were approved by Auckland Hospital (3435), NZ Ministry of Health (MEC/06/10/134), and the Walter and Eliza Hall Institute (WEHI) Human Research Ethics Committee (HREC 10/02).

Compliance with Ethical Standards

Conflict of Interest

All authors declare they have no conflicts of interest.

Authorship

RA- wrote the first draft.

KL- wrote bioinformatics section.

STW, DG, and RS edited and revised the manuscript.

CS and VB contributed to the text.

References

  1. 1.
    Gathmann B, Mahlaoui N, Gerard L et al (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 134(1):116–126CrossRefPubMedGoogle Scholar
  2. 2.
    Chapel H, Lucas M, Lee M et al (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112(2):277–286CrossRefPubMedGoogle Scholar
  3. 3.
    Ameratunga R, Becroft DM, Hunter W (2000) The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology 32(4):280–282CrossRefPubMedGoogle Scholar
  4. 4.
    Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R (2013) New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 174(2):203–211PubMedPubMedCentralGoogle Scholar
  5. 5.
    Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R (2014) New diagnostic criteria for CVID. Expert Rev Clin Immunol 10(2):183–186CrossRefPubMedGoogle Scholar
  6. 6.
    Koopmans W, Woon ST, Zeng IS et al (2013) Variability of memory B cell markers in a cohort of common variable immune deficiency patients over six months. Scand J Immunol 77(6):470–475CrossRefPubMedGoogle Scholar
  7. 7.
    Ameratunga R, Barker R, Steele R et al (2015) Profound reversible hypogammaglobulinemia caused by celiac disease in the absence of protein losing enteropathy. J Clin Immunol 35(6):589–594CrossRefPubMedGoogle Scholar
  8. 8.
    Ameratunga R, Lindsay K, Woon S-T, Jordan A, Anderson NE, Koopmans W (2015) New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol 6(1):83–88CrossRefGoogle Scholar
  9. 9.
    Ameratunga R, Storey P, Barker R, Jordan A, Koopmans W, Woon ST (2015) Application of diagnostic and treatment criteria for common variable immunodeficiency disorder. Expert Rev Clin Immunol 12(3):257–266CrossRefGoogle Scholar
  10. 10.
    Ameratunga RV, Parry S, Kenedi C (2013) Hypogammaglobulinemia factitia- Munchausen syndrome presenting as common variable immune deficiency. Allergy Asthma Clin Immunol. 9(36)Google Scholar
  11. 11.
    Ameratunga R, Brewerton M, Slade C et al (2014) Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol 5:415CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bonilla FA, Barlan I, Chapel H et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4(1):38–59CrossRefPubMedGoogle Scholar
  13. 13.
    Oksenhendler E, Gerard L, Fieschi C et al (2008) Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 46(10):1547–1554CrossRefPubMedGoogle Scholar
  14. 14.
    Conley ME, Notarangelo LD, Etzioni A (1999) Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93(3):190–197CrossRefPubMedGoogle Scholar
  15. 15.
    Empson M, Sinclair J, O'Donnell J, Ameratunga R, Fitzharris P, Steele R (2004) The assessment and management of primary antibody deficiency. N Z Med J 117(1195):U914PubMedGoogle Scholar
  16. 16.
    Ameratunga R, Gillis D, Steele R (2016) Diagnostic criteria for common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4(5):1017–1018CrossRefPubMedGoogle Scholar
  17. 17.
    Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med: Off J Am Coll Med Genet 17(5):405–424CrossRefGoogle Scholar
  18. 18.
    Woon ST, Ameratunga R. Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New Zealand. Allergy Asthma Clin Immunol 2016;12:65Google Scholar
  19. 19.
    Ameratunga R, Winkelstein JA, Brody L et al (1998) Molecular analysis of the third component of canine complement (C3) and identification of the mutation responsible for hereditary canine C3 deficiency. J Immunol 160(6):2824–2830PubMedGoogle Scholar
  20. 20.
    Bacchelli C, Buckland KF, Buckridge S et al (2011) The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice. J Allergy Clin Immunol 127(5):1253–1259 e1213 CrossRefPubMedGoogle Scholar
  21. 21.
    Ameratunga R, Bartlett A, McCall J, Steele R, Woon ST, Katelaris CH (2016) Hereditary angioedema as a metabolic liver disorder: novel therapeutic options and prospects for cure. Front Immunol 7:547CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fliegauf ML, Bryant V, Frede N et al (2015) Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet 97(3):389–403CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F (2016) Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet. 53(9):575–590.  https://doi.org/10.1136/jmedgenet-2015-103690
  24. 24.
    Raje N, Soden S, Swanson D, Ciaccio CE, Kingsmore SF, Dinwiddie DL (2014) Utility of next generation sequencing in clinical primary immunodeficiencies. Curr Allergy Asthma Rep 14(10):468CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Grimbacher B, Warnatz K, Yong PF, Korganow AS, Peter HH (2016) The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects. J Allergy Clin Immunol 137(1):3–17 quiz 18CrossRefPubMedGoogle Scholar
  26. 26.
    Ameratunga R, Woon ST, Brewerton M et al (2011) Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann N Y Acad Sci 1238:53–64CrossRefPubMedGoogle Scholar
  27. 27.
    Ameratunga R, Woon ST, Neas K, Love DR (2010) The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review. Allergy Asthma Clin Immunol 6(1):12CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ameratunga R, Steele R, Jordan A et al (2016) The case for a national service for primary immune deficiency disorders in New Zealand. N Z Med J. 129(1436):75–90PubMedGoogle Scholar
  29. 29.
    Ameratunga R, Woon ST (2009) Customised molecular diagnosis of primary immune deficiency disorders in New Zealand: an efficient strategy for a small developed country. N Z Med J 122(1304):46–53PubMedGoogle Scholar
  30. 30.
    Rodriguez-Cortez VC, Del Pino-Molina L, Rodriguez-Ubreva J et al (2015) Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naive-to-memory B-cell transition. Nat Commun 6:7335CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    van Schouwenburg PA, Davenport EE, Kienzler AK et al (2015) Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. Clin Immunol 160(2):301–314CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kienzler AK, Hargreaves CE, Patel SY (2017) The role of genomics in common variable immunodeficiency disorders. Clin Exp Immunol 188(3):326–332CrossRefPubMedGoogle Scholar
  33. 33.
    Ameratunga R, Koopmans W, Woon ST, et al. Epistatic interactions between mutations of TACI (TNFRS13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. Clin Transl Immunol (Nature). 2017;(in press)Google Scholar
  34. 34.
    Bateson (1909) Discussion on the influence of heredity on disease, with special reference to tuberculosis, cancer, and diseases of the nervous system: introductory address. Proc R Soc Med;2(Gen Rep):22–30Google Scholar
  35. 35.
    Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R (2013) Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol 33(1):68–73CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Rohan Ameratunga
    • 1
    Email author
  • Klaus Lehnert
    • 2
  • See-Tarn Woon
    • 1
  • David Gillis
    • 3
  • Vanessa L. Bryant
    • 4
    • 5
    • 6
  • Charlotte A. Slade
    • 4
    • 5
    • 6
  • Richard Steele
    • 1
  1. 1.Auckland HospitalAucklandNew Zealand
  2. 2.University of AucklandAucklandNew Zealand
  3. 3.Royal Brisbane HospitalBrisbaneAustralia
  4. 4.Department of ImmunologyWalter and Eliza Hall Institute of Medical ResearchParkvilleAustralia
  5. 5.Department of Medical BiologyUniversity of MelbourneParkvilleAustralia
  6. 6.Department of Allergy and Clinical Immunology, Royal Melbourne HospitalParkvilleAustralia

Personalised recommendations